IAVI Report
IAVI Report is a scientific publication that provides comprehensive and editorially independent coverage of HIV vaccine and prevention research, as well as the quest to develop vaccines and other preventive technologies to address other global health priorities. The publication features the voices and opinions of those leading these efforts and provides an unparalleled analysis of the latest scientific and policy research.
To access archived issues of IAVI Report dating back to 1996, click here.
Subscribe now to receive IAVI Report right to your inbox.
Questions/comments? Email us at This email address is being protected from spambots. You need JavaScript enabled to view it..
Key Words Search
- Editor's Letter
-
A step in the right direction
Researchers describe the experimental HIV vaccine approach called germline targeting as “shepherding” the immune system. They hope it will lead to greener pastures.
-
Leading Africa’s COVID-19 response
John Nkengasong warns against complacency setting in as vaccines trickle into many African countries.
-
A tale of two pandemics
In conversation with four experts who are applying lessons from the decades-long battle against HIV/AIDS to the ongoing COVID-19 pandemic.
-
The future of antibody-based HIV prevention
The highly anticipated results from recent HIV prevention trials, and how the field acts on them, may have important implications for future research. This special report identifies the main issues researchers are contemplating in the aftermath of the first trials to test whether a broadly neutralizing antibody could protect people from HIV infection. Read more to find out what 21 leading experts in the field have to say about the future of antibody-based HIV prevention.
- Editor's Letter
-
The race is on
Scientists are applying decades of HIV research experience to the development of SARS-CoV-2 vaccines in the race to end the pandemic.
-
Monoclonal antibodies and their potential role in combatting COVID-19
Numerous monoclonal antibodies are already in development for both treatment and prevention. There are many unanswered questions, but, if they work, antibodies may play a role in ending this...
-
Finding a global solution for a global problem
An interview with Seth Berkley, chief executive officer of Gavi, the Vaccine Alliance
-
In the midst of a pandemic and preparing for the next
SARS-CoV-2 is the first Disease X. There will certainly be others. Will the world be better prepared for the next one?
- Editor's Letter
-
Proven against Ebola, a vector shows its broader potential
Regulatory approval of a vesicular stomatitis virus-based vaccine paves the way for use of this viral vector in other vaccines.
-
Turning the tide on TB?
A slew of potential advances in treating and preventing tuberculosis offers new hope in the battle against one of the oldest human afflictions.
-
Vaccines: adapting to the times
Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.
-
Taking the next step with the mosaic HIV vaccine candidate
Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of...
-
Could vaccines reach remote areas … remotely?
Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.
- Editor's Letter
-
‘We’re moving in the right direction’
A conversation with Anatoli Kamali and Penny Moore about the rise of HIV vaccine science in Africa
-
The best is yet to come
Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.
-
Stopping HIV where it starts
Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.
-
Upcoming efficacy trial illustrates the value of African-led science
We must continue to engage local investigators and develop their capacity to conduct more basic and clinical research on the African continent.
- Editor's Letter
-
Is there an HIV prevention crisis?
More HIV-infected people than ever before are receiving life-saving treatment. Despite this progress, HIV incidence rates remain virtually static.
-
Coding for protection
Although challenges remain, the growing field of mRNA-based vaccine development seems to have a bright future, with potential for preventing cancer, flu, and HIV.
-
An industry leader in HIV research
Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.
-
Overflowing with antibodies and optimism
There is more optimism than ever that researchers are on the path to developing vaccines and antibodies that can help stem HIV’s persistent spread.
- Editor's Letter
-
Could overly optimistic messages be contributing to the drop in global HIV/AIDS spending?
The pandemic isn’t over, but that might be what donors are hearing.
-
A new generation of engineered vaccine candidates enters clinical testing
After decades of work, scientists are now advancing rationally designed vaccine candidates meant to induce a long sought-after broadly neutralizing antibody response.
-
Remembering Adel Mahmoud, a giant in the vaccine world
By Kristen Jill Kresge The vaccine world lost another of its great leaders recently with the passing of Adel Mahmoud, a physician, scientist, and professor who played a critical role in the...
-
A fast track for vaccine development
Coalition awards US$174 million in grants for research targeting Nipah virus, Lassa fever, and MERS.
-
HIV vaccine efforts herald a new era of vaccinology
By Mark Feinberg, MD, PhD We are at a defining moment in the history of HIV vaccine research. It is not an exaggeration to also propose that, thanks to the fruits of decades of HIV vaccine research and...
-
Igniting passion for the long haul
Linda-Gail Bekker talks about how she came to work on HIV and shares her thoughts on an evolving field.
- Editor's Letter
-
Applying Innovative Approaches and Technologies to HIV Prevention
Several areas of progress in using antibodies for HIV prevention were showcased at the recent Keystone Symposia.
-
A Mean Flu Season Swings a Spotlight on Vaccines
Influenza, like HIV, is a highly variable menace. A particularly bad flu season has researchers seeking ways to make a better vaccine, and in doing so, there may be lessons from, and for, HIV...
-
Drawing Lessons from AIDS to Prevent Future Epidemics
Jonathan Quick describes how the right mix of science, funding, leadership, and communication can come together to secure the world against future epidemics.
-
Remembering David Cooper: A Great Leader in HIV Epidemiology, Treatment, and Prevention
The battle against HIV/AIDS lost another great soldier recently with the passing of Australian immunologist and clinician David Cooper on March 18. Cooper was a pioneering scientist and champion for HIV...
-
"She was the best of us"
Remembering Bonnie Mathieson: A champion of young scientists At the Annual Scientific Retreat in 2016 for the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Design (CHAVI-ID), Bonnie...
